[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BioSensics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":159},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,69,88,112,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100611455","digital-health-technologies-for-progressive-supranuclear-palsy-and-dementia-with-lewy-bodies-100611455",false,"NCT07240805","Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Digital Health Technologies For Monitoring Disease Symptoms in Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Inclusion Criteria:\n\n* Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB.\n* Able to be present for all study procedures, complete questionnaires and assist during home data collection.\n* Eligible participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n* Ambulatory (able to take 10 steps with minimal support such as use of a cane)\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.","ALL","40 Years","89 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.",[25,26,27,28,29],"Progressive Supranuclear Palsy(PSP)","Dementia With Lewy Bodies (DLB)","PSP","Lewy Body Dementia (LBD)","Lewy Body Disease","NOT_YET_RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":21},"2026-06-15",{"date":38,"type":21},"2029-01-01",{"name":40,"class":41},"BioSensics","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100636721","a-wearable-sensor-platform-for-remote-monitoring-of-individuals-on-the-frontotemporal-dementia-spectrum-100636721","NCT07569367","A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum","ReMoTe","Inclusion Criteria:\n\n* Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.\n* Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* Individuals who have a history of frequent falls defined as more than 5 falls per month.",{"count":20,"type":21},"The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.",[53,54,55,56],"Frontotemporal Lobar Degeneration (FTLD)","Frontotemporal Dementia (FTD)","Corticobasal Degeneration","Corticobasal Syndrome (CBS)",[58,59,60],"digital health","wearable sensors","frontotemporal lobar degeneration","2026-05-05",{"date":63,"type":34},"2026-05-08",{"date":65,"type":21},"2026-08-01",{"date":67,"type":21},"2030-12-15",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100618613","digital-measurements-of-motor-and-voice-functions-in-ftd-100618613","NCT07333898","Digital Measurements of Motor and Voice Functions in FTD",{"count":75,"type":21},20,"The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with FTLD syndromes.\n\nResearchers at BioSensics and Johns Hopkins School of Medicine will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 20 patients with FTLD syndromes for 12 months with study visits every 3 months.",[53,54,78,79,55],"Corticobasal Syndrome","Corticobasal Syndrome(CBS)",[58,59,60],"2026-04-23",{"date":83,"type":34},"2026-04-28",{"date":65,"type":21},{"date":86,"type":21},"2028-12-31",{"name":40,"class":41},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":16,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":111,"locationsCount":42},"100617235","multi-modal-digital-monitoring-of-disease-symptoms-huntingtons-disease-100617235","NCT07315984","Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease","BioDigit HD-02","Inclusion Criteria:\n\n* Male or female, aged 25-65 years\n* For HD participants: Genetically diagnosed with HD\n* Fluent in English (able to speak and read).\n* Ambulatory without the need for a walking aid.\n* Able to independently perform all study activities safely, as determined by the investigator.\n* Willing and able to provide informed consent and comply with all study procedures.\n\nFor control participants:\n\n* Male or female, aged 25-65 years\n* Clinically assessed to be in good health, with no evidence of neurological disorders that could cause involuntary movements or gait disturbances\n\nExclusion Criteria:\n\n* Diagnosis of juvenile-onset HD.\n* Individuals who are non-ambulatory.\n* Individuals with a neurological, medical, or psychiatric condition that, in the investigator's judgment, would interfere with safe participation in study activities.\n* Montreal Cognitive Assessment (MoCA) score of 18 or lower\n* Pregnant individuals, due to potential changes in gait and physical activity during pregnancy.\n* Cannot be enrolled into a blinded intervention trial at baseline.",true,"25 Years","65 Years",{"count":99,"type":21},75,"The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD). Healthy subjects, as well as subjects with documented diagnosis of HD will be screened and recruited at University of Rochester Medical Center and Vanderbilt University Medical Center to participate in this 12-month observational study. There will be a total of 5 visits every approximately 3 months.\n\nIn each study visit, participants will complete several Patient Reported Outcomes (PROs), Clinical Reported Outcomes, complete a series of Digital Assessments (Speech, Cognitive, Motor, and Finger Tapping). Participants will be provided with a pendant, wrist, and ankle sensors to monitor their daily physical activities for 7 days after each study visit. Participants will also be provided with a tablet to complete digital assessments (Speech, Cognitive, Motor, and Finger Tapping) on monthly basis at home.",[102],"Huntington Disease",[104,59,58],"huntington disease","2025-12-31",{"date":107,"type":34},"2026-01-05",{"date":109,"type":21},"2026-01-31",{"date":86,"type":21},{"name":40,"class":41},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100610380","quantification-of-change-in-mg-disease-activity-in-individuals-with-generalized-myasthenia-gravis-gmg-after-administration-of-vyvgart-or-vyvgart-hytrulo-using-biodigit-mg-100610380","NCT07226830","Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG","BioDigit MG-03","Inclusion Criteria:\n\n* Diagnosis of autoimmune MG with or without history of thymoma\n* MGFA severity class IIa\u002Fb, IIIa\u002Fb or IVa\u002Fb at the screening visit\n* Diagnosed gMG through one or more of the following:\n* Positive acetylcholine receptor antibody (AChR Ab) test, or\n* Abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS), or\n* Documented positive response to standard MG therapies (e.g., AChE inhibitors, IVIG\u002FPLEX, FcRn antagonists or C5 inhibitors)\n* Currently initiating treatment with VYVGART® or VYVGART Hytrulo®\n* Physically and cognitively able to provide informed consent and adhere to the study procedures, as determined by the investigator.\n* Ambulatory, defined as the ability to walk at least 10 meters independently, with or without the use of an assistive device.\n* Speaks and reads English fluently\n\nExclusion Criteria:\n\n* Inability to perform essential activities of daily living required for independent living, such as dressing, bathing, toileting, or eating without assistance.\n* Presence of neurological or orthopedic conditions unrelated to MG that, in the investigator's judgment, significantly impair gait or daily functioning.\n* Any clinically significant medical, laboratory, or psychiatric condition that, in the opinion of the investigator, could interfere with study participation or data integrity.\n* Current residence in a long-term care or institutional facility (e.g., nursing home, skilled nursing facility), receipt of hospice care, or incarceration.\n* MGFA severity classification of Class I or Class V (myasthenic crisis). Pregnant or breastfeeding women.\n* Concurrent participation in another interventional clinical trial (participation in observational studies, biomarker studies, or registries is permitted).","18 Years","80 Years",{"count":122,"type":21},25,"Evaluate the feasibility of using digital health technologies to monitor disease symptoms over time in individuals with gMG who are initiating treatment with VYVGART® or VYVGART Hytrulo®.\n\nStudy subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 16 week observational study.\n\nStudy subjects will be asked to wear multiple wearable sensors to monitor their physical activity and PPG during daily activities. Participants will also complete speech, video, and ePRO and eCOA digital assessments at home and during study visits.\n\nThe primary objective of this observational clinical study is to remotely evaluate MG-specific outcomes using digital health technologies in individuals with gMG during two treatment cycles with VYVGART® or VYVGART Hytrulo®.",[125],"Myasthenia Gravis Generalized",[127,58,59],"myasthenia gravis","2025-11-09",{"date":130,"type":34},"2025-11-12",{"date":132,"type":21},"2026-01-15",{"date":134,"type":21},"2028-03-31",{"name":40,"class":41},1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":136},"100610192","multi-modal-monitoring-of-disease-symptoms-in-myasthenia-gravis-100610192","NCT07224386","Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis","BioDigit MG-02","Inclusion Criteria:\n\n* Autoimmune MG with or without history of thymoma, MGFA severity Class IIa\u002Fb, IIIa\u002Fb or IVa\u002Fb at the screening visit\n* Diagnosed gMG through ONE of the following methods:\n\n  * Positive acetylcholine receptor antibody (AChR Ab) test\n  * Positive muscle specific kinase receptor antibody (MuSK Ab) test\n  * Positive LRP4 antibody and abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS) OR has maintained a positive response to treatments such as AChE inhibitors, IVIG\u002FPLEX, FcRn antagonists or C5 inhibitors\n  * Abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS) OR has maintained a positive response to treatments such as AChE inhibitors, IVIG\u002FPLEX, FcRn antagonists or C5 inhibitors.\n* Physically and cognitively able to provide informed consent and adhere to the protocol, as determined by the investigator's judgment\n* Ambulatory status defined as the ability to walk a distance of 10 meters independently, with or without the use of an assistive device\n* Male or female, between the ages of 18 years old and 80 years old\n* Speaks and reads English fluently\n\nExclusion Criteria:\n\n* Inability to engage in activities that are essential for independent living, such as dressing, bathing, toileting, or eating independently.\n* Neurological or orthopedic problems independent of myasthenia which significantly affect gait and ADLs in the investigator's judgement.\n* Any significant medical, laboratory, or psychiatric condition that, in the judgment of the investigators, would potentially interfere with the ability to participate in the study.\n* Residence in long-term care centers or institutions, nursing facilities, skilled nursing facilities, or recipients of hospice care, or incarceration.\n* MGFA severity class I or V (MG crisis)\n* Pregnant women.\n* Concurrent participation in an interventional clinical trial (observational studies, biomarker studies and registries are acceptable)",{"count":145,"type":21},50,"Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG).\n\nStudy subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 12 month observational study. Study subjects will be asked to wear multiple wearable sensors to monitor their physical activity and PPG during daily activities. Participants will also complete speech, video, and ePRO and eCOA digital assessments at home and during study visits.\n\nThe primary objective for this observational study is to measure the correlation of sensor-derived measures of physical activity to MG-specific ratings of MG-ADL, QMG, MGC, and Neuro-QoL Fatigue",[148,149],"Myasthenia Gravis","Myasthenia Gravis, Generalized",[127,58,59],"2025-10-31",{"date":153,"type":34},"2025-11-04",{"date":155,"type":21},"2026-01-01",{"date":157,"type":21},"2028-04-30",{"name":40,"class":41},""]